Zentalis Pharmaceuticals Q3 EPS $(0.96) Down From $(0.09) YoY
Zentalis Pharmaceuticals (NASDAQ:ZNTL) reported quarterly losses of $(0.96) per share. This is a 966.67 percent decrease over losses of $(0.09) per share from the same period last year.
Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration With Pfizer
Zentalis™ Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers
Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX dose groups.
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.
Morgan Stanley Maintains Overweight on Zentalis Pharmaceuticals, Lowers Price Target to $60
Morgan Stanley analyst Matthew Harrison maintains Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Overweight and lowers the price target from $95 to $60.
This Analyst Says Zentalis’ Increased Focus On WEE1 Program Is ‘Prudent’, Slashes Price Target By 37%
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) decided to discontinue the development of oral SERD asset ZN-c5 and EGFR inhibitor ZN-e4 following the completion…
SVB Leerink Maintains Outperform on Zentalis Pharmaceuticals, Lowers Price Target to $42
SVB Leerink analyst Andrew Berens maintains Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform and lowers the price target from $67 to $42.
Zentalis Pharmaceuticals: Q2 Earnings Insights
Zentalis Pharmaceuticals (NASDAQ:ZNTL) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.